Start 30 days free, no card. Full Pro access for a month, then decide. Start free
Analyst
John Purtell
Period: Reporting periods mapped to calendar 2024 Q3 – 2026 Q2 (8 quarters).
- Questions
- 8on tracked calls
- Challenge rate
- 0%none of 8 questionsLimited sample
- Companies
- 1questioned at least once
- Reporting periods
- 8with questions
These figures cover the whole profile: every tracked question, all reporting periods.
How to read these numbers
Challenge rate is the share of questions that pushed back, pressed for specifics or questioned management’s assumptions. It describes how questions were asked on the calls tracked here; it does not measure whether any view turned out to be right.
Rounding. Rates are rounded to whole percentages, so a small share can show as 0% even when some questions were challenging. The count beside each rate is exact; “none of N questions” means no question was challenging.
No questions recorded. “—” means there is nothing to calculate: no questions were recorded for that period on the calls tracked here. It does not mean there was no activity.
Fewer than 3 questions. A company-level rate is withheld when fewer than 3 questions were recorded for that company; the questions are still counted everywhere else.
Small samples. Profiles with fewer than 10 questions are marked Limited sample.
Reporting periods. Questions are grouped by the calendar quarter each company’s fiscal reporting period maps to, not by the date of the call. Periods without a calendar mapping are listed separately under their fiscal label.
Questions asked
Grouped by company, most questions first. Open a company to read its questions, newest reporting period first.
Showing 8 of 8 questions from 1 company
AMCRAmcor8 questions · 8 reporting periods · 0 of 8 challenging
Calendar 2026 Q2
How much of that do you expect to get back in the next 6 months as distinct from 12?
Show response
Steve expected to recover the cumulative ~$500 million (up from an original $300 million estimate, the $200 million increase largely accounts-receivable driven) over 12 months, with $100-300 million in the first 6 months, plus structural targets across inventory days, DSO and days payable.
Calendar 2026 Q1
just how you see it profiling over the next sort of 12 months
Show response
Steve explained year-end 3.4-3.5x driven by modestly lower EBITDA (volumes -2% vs flat assumption) and $300M inventory impact. Line of sight to 3x through divestitures, synergy capture, and cash flow. Calendar/fiscal 2027 expected to be important inflection year.
Calendar 2025 Q4
I'd be interested in your perspectives on the synergy opportunity with Berry, and also how you see plastic versus other substrates
Show response
Steve praised Amcor's capabilities, integration discipline, and synergy tracking. Noted rigid and flexible packaging has broad right-to-win globally as fit-for-purpose in consumer daily life, complementary to fiber-based packaging which has its own niche.
Calendar 2025 Q3
can you just talk to the sort of, I suppose, the underlying sort of cost and productivity piece because it does imply that there's been some pretty good costs and productivity management there
Show response
Michael detailed proactive cost management including shift patterns, line performance optimization, discretionary spend reduction. Synergy delivery at $38M (upper end) included G&A and procurement. Revenue synergy pipeline also building. Ability to flex costs demonstrated.
Calendar 2025 Q2
just to clarify any market share shifts to call out as well as any -- just in terms of, I suppose, talking to the volume performance
Show response
PK confirmed volume weakness driven entirely by consumer/customer demand, not share loss or destocking. Healthcare destocking fully behind. Any inventory movements are seasonal or tactical, not structural.
Calendar 2025 Q1
what you saw within the quarter and any comment you can make on April
Show response
PK acknowledged demand weakened through Q3, particularly in North America. Q4 expectation: flat volumes from Amcor side plus slight growth from 2 months Berry contribution, resulting in flat to slightly positive.
Calendar 2024 Q4
obviously, Berry globalizes your Rigids business. I mean, what do you see as the sort of key benefits of that?
Show response
PK detailed complementary fit: Amcor's $3B Rigids (NA beverage + specialty containers) combines with Berry's $7B containers/closures. Berry does not overlap on NA beverage. Healthcare delivery systems and dispensing/pumps are key attractions.
Calendar 2024 Q3
Just on Q1 volume growth, just confirming that sort of broadly where you thought it would be
Show response
PK confirmed volumes broadly in line with expectations and provided detailed breakdown showing Flexibles up 5% ex-healthcare, with pharma destocking expected to abate by end of Q2.
Challenge rate by company
Every company this analyst questioned, most questions first. A company-level rate is shown from 3 questions; below that it is withheld.
| Company | Questions | Challenge rate |
|---|---|---|
| AMCR Amcor | 8 | 0%none of 8 questions |
- AMCRAmcor · 8 questions0%none of 8 questions
Activity by reporting period
Questions recorded for each calendar quarter that companies’ reporting periods map to (not the call date), with the challenge rate for that period. Periods inside the range with no questions are shown as “No questions recorded”.
| Calendar period | Questions | Challenge rate | Companies |
|---|---|---|---|
| 2024 Q3 | 1 | 0%none of 1 question | 1 |
| 2024 Q4 | 1 | 0%none of 1 question | 1 |
| 2025 Q1 | 1 | 0%none of 1 question | 1 |
| 2025 Q2 | 1 | 0%none of 1 question | 1 |
| 2025 Q3 | 1 | 0%none of 1 question | 1 |
| 2025 Q4 | 1 | 0%none of 1 question | 1 |
| 2026 Q1 | 1 | 0%none of 1 question | 1 |
| 2026 Q2 | 1 | 0%none of 1 question | 1 |
- 2024 Q31 question · challenge rate 0% (none of 1 question) · 1 company
- 2024 Q41 question · challenge rate 0% (none of 1 question) · 1 company
- 2025 Q11 question · challenge rate 0% (none of 1 question) · 1 company
- 2025 Q21 question · challenge rate 0% (none of 1 question) · 1 company
- 2025 Q31 question · challenge rate 0% (none of 1 question) · 1 company
- 2025 Q41 question · challenge rate 0% (none of 1 question) · 1 company
- 2026 Q11 question · challenge rate 0% (none of 1 question) · 1 company
- 2026 Q21 question · challenge rate 0% (none of 1 question) · 1 company
Topics
Topics tagged on this analyst’s questions.
- Demand3
- Capital Allocation2
- M&A2
- Competitive Dynamics2
- Revenue Growth2
- Supply Chain1
- Margin1
- Cost Pressure1
- Inventory1